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Abstract
Background: Molecular mechanisms underlying prion agent replication, converting host-encoded
cellular prion protein (PrPC) into the scrapie associated isoform (PrPSc), are poorly understood.
Selective self-interaction between PrP molecules forms a basis underlying the observed differences
of the PrPC into PrPSc conversion process (agent replication). The importance of previously
peptide-scanning mapped ovine PrP self-interaction domains on this conversion was investigated by
studying the ability of six of these ovine PrP based peptides to modulate two processes; PrP self-
interaction and conversion.
Results: Three peptides (octarepeat, binding domain 2 -and C-terminal) were capable of inhibiting
self-interaction of PrP in a solid-phase PrP peptide array. Three peptides (N-terminal, binding
domain 2, and amyloidogenic motif) modulated prion conversion when added before or after
initiation of the prion protein misfolding cyclic amplification (PMCA) reaction using brain
homogenates. The C-terminal peptides (core region and C-terminal) only affected conversion
(increased PrPres formation) when added before mixing PrPC and PrPSc, whereas the octarepeat
peptide only affected conversion when added after this mixing.
Conclusion: This study identified the putative PrP core binding domain that facilitates the PrPC-
PrPSc interaction (not conversion), corroborating evidence that the region of PrP containing this
domain is important in the species-barrier and/or scrapie susceptibility. The octarepeats can be
involved in PrPC-PrPSc stabilization, whereas the N-terminal glycosaminoglycan binding motif and
the amyloidogenic motif indirectly affected conversion. Binding domain 2 and the C-terminal
domain are directly implicated in PrPC self-interaction during the conversion process and may
prove to be prime targets in new therapeutic strategy development, potentially retaining PrPC
function. These results emphasize the importance of probable PrPC-PrPC and required PrPC-PrPSc
interactions during PrP conversion. All interactions are probably part of the complex process in
which polymorphisms and species barriers affect TSE transmission and susceptibility.
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Background
Transmissible spongiform encephalopathies (TSEs) are
fatal neurodegenerative disorders characterized by accu-
mulation of the pathological isoform of prion protein
mainly in tissues of the central nervous system. Formation
of this pathological isoform is a posttranslational process
and involves refolding (conversion) of the host-encoded
prion protein (PrPC) into a pathological isoform partially
protease resistant PrPSc (derived from scrapie) or PrPres
(PK-resistant PrP) [1]. The molecular mechanisms
involved in PrPC to PrPSc conversion are poorly under-
stood, but polymorphisms in both PrP isoforms have
been shown to be of importance in both interspecies and
intraspecies transmissibilities [2]. The formation of PrPSc
aggregates probably requires self-interactions of PrPC mol-
ecules as well as with PrPSc [3,4]. Thus binding and con-
formational changes are essential events in this
conversion process. Cell-free conversion of PrPC provides
a valuable in vitro model in which relative amounts of pro-
duced PrPres reflect important biological aspects of TSEs at
the molecular level [5,6]. A recent and very sensitive in
vitro conversion system is the protein misfolding cyclic
amplification (PMCA) assay [7-10], which has been
shown to amplify minute amounts of PrPSc from a variety
of sources including sheep scrapie [10]. The effects of sin-
gle polymorphisms and species-barriers in PrPC or PrPSc
on PrP conversion can largely explain differences in sus-
ceptibility -and transmissibility in sheep scrapie [5,11-
13]. Even though these polymorphisms are involved in
modulation of disease development they do not seem to
affect the initial binding of PrPC to PrPSc [14] and do not
seem to directly modulate PrPC-PrPSc binding. Further-
more, in a recent peptide-array mapping study of ovine
PrPC we concluded that these polymorphisms are not part
of the identified PrP binding domains likely to be
involved in PrP self-interaction [15]. However, this does
not exclude these polymorphisms from posing indirect
effects on binding behaviour of PrPC to PrPSc and other
possible chaperoning molecules. In that peptide-array
binding study we unequivocally demonstrated that ovine
PrP binds with PrP derived (self) amino acid sequences
(sequence specific) separate from the polymorphic scrapie
susceptibility determinants [15]. It remains to be eluci-
dated whether the determined amino acid sequences play
a role prior or during conversion in the self-interaction of
PrPC molecules and/or in the interactions of PrPC with
PrPSc. Simultaneously, whether these amino acid
sequences play a role in the processes underlying PrP con-
version needs to be elucidated. In the current study we
selected several ovine PrP sequence derived synthetic pep-
tides to study not only their capacity to affect PrP binding
to a solid-phase (PrP) peptide-array but also their poten-
tial modulating effect on PrPC to PrPSc conversion.
Results
Previously we determined that recombinant ovine PrP
yielded a reproducible sequence specific binding pattern
with amino acid sequences using a solid-phase array of
overlapping 15-mer peptides encompassing the complete
ovine -or bovine amino acid sequence (peptide-array).
Roughly this pattern breaks down into two high binding
areas containing two-and three consensus domains
respectively, combined with some lower binding domains
(Figure 1). Based on the interaction domains extrapolated
from this binding pattern as well as properties reported in
literature, the following six ovine PrP regions were
selected for peptide blocking studies. The sequences of
these peptides represented structural properties of PrP as
explained hereafter (summarized in table 1 and mapped
in figure 1): Peptide NTG, spanning the amino acids
(AAs) at the N-terminal part of the mature PrPC, including
the glycosaminoglycan (GAG) binding motif KKRPK [16]
and binding domain 1 [27-RPKPGGG-33] (ovine num-
bering used throughout, [15] and this study); Peptide OR,
spanning the octarepeat AA motif [QPHGGGWG, AA 54-
94] of the N-terminal region (PrP self-interaction was
mapped to AA motif P(H)GG [15]), which is probably
involved in a range of interactions [17-31] of which
metal-binding is the best characterized; Peptide TD2,
which overlaps the limiting region containing strain and
species dependant variable sites for proteinase K trimming
of PrPSc [32,33] and spanning binding domain 2 ([102-
WNK-104], ovine numbering used throughout) of the
first high binding area [15]; Peptide AM, which includes
the amyloidogenic motif (AGAAAAGA) of PrP that did
not exhibit any binding in the peptide-array [15]; Peptide
CO, encompassing amino acids of the core region of PrP
spanning from the first β-sheet onto the first α-helix. The
peptide includes binding domain 3 [140-PLIHFGNDYE-
149] and is immediately adjacent to binding domain 4a of
the second high binding area [15]; These domains are also
important in PrPSc  conformation-specific immuno-pre-
cipitation [34-40]; and peptide CT, spanning the C-termi-
nal AA's covering part of the third helix, partially covering
low binding domain 6 [192-TTTTKGENFT-202] and
almost identical to a peptide capable of inhibiting cell-
free conversion [41].
PrP peptide inhibition of PrP self-binding to peptide-array
First these six peptides were tested for their capability to
inhibit PrP binding to the PrP based peptide-array con-
taining 242 peptides (15-mer) overlapping each other by
increments of 1 AA, covering the complete ovine PrP
amino acid sequence (results summarized in Table 1).
Pre-incubation of PrP with peptide CO did not result in
blocking of the binding pattern of PrP on the peptide-BMC Biochemistry 2009, 10:29 http://www.biomedcentral.com/1471-2091/10/29
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PrPC secondary structures and relative peptide positions versus peptide-array binding pattern and binding domain positions Figure 1
PrPC secondary structures and relative peptide positions versus peptide-array binding pattern and binding 
domain positions. Schematic representation of PrPC showing signal sequences, β-sheets (S1, S2), α-helices (H1, H2, H3), 
disulfide bridge (S-S), glycosylation sites (CHO) and the relative positions of the peptides used in this study. The bar graph rep-
resents the previously determined peptide-array binding pattern [15] and the relative positions of the determined interaction 
domains: 1 [27-RPKPGGG-33], A-E octarepeat motif [PxGG], 2 [102-WNK-104], 3 [140-PLIHFGNDY-148], 4a [152-YYR-
154], 4b [165-YYR-167], 5 [177-NFV-179] and 6 [225-SQAY-228]. All numbering used is for sheep PrP.
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Table 1: Peptide information and peptide-array blocking results
peptide amino acid sequence position1 block2 equiv.3
NTG KKRPKPGGGWNT 25-36 +/- 403
OR GQPHGGGWGQ 61-95 ++ 396
TD2 GGGGWGQGGSHSQWNKPSK 89-107 ++ 198
AM KTNMKHVAGAAAAGA 109-123 +/- 502
CO LGSAMSRLPLIHFGNDYEDR 133-151 no 499*
CT GENFTETDIKIMERVVEQMC 198-217 ++ 198
1 position of the amino acid sequence in mature ovine PrPC
2 effect of pre-incubation with peptide on binding of PrP to the peptide-array
(-- no effect, +/- moderate blocking, ++ blocking)
3 minimal amount of molar excess of peptide needed to affect PrP binding
(* highest amount of excess peptide tested)BMC Biochemistry 2009, 10:29 http://www.biomedcentral.com/1471-2091/10/29
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array (Figure 2a), whereas peptides NTG and AM only
moderately blocked the binding pattern of PrP (Figure
2b). Peptide NTG seems to diminish binding throughout
the binding pattern (Figure 2b, blue line), whilst peptide
AM mainly affects binding with the peptides derived from
the N-terminal part of mature PrP (Figure 2b, green line).
Maximum blocking throughout the PrP binding pattern
occurred with peptides OR (Figure 2c, blue line), TD2
(Figure 2c, green line) and CT (Figure 2c, orange line),
which all block equally throughout the PrP binding pat-
tern. However, in contrast to blocking studies performed
with antibodies [15], blocking was not absolute over the
whole region of the PrP peptide-array binding pattern.
Inhibition by the aforementioned peptides was dose-
dependant, with maximum blocking only occurring when
peptides were added at high molecular ratios to PrP. Pre-
incubation of PrP with (at least) 400 times molar excess of
peptide OR or (at least) 200 times molar excess of pep-
tides TD2 and CT was necessary to obtain maximum
blocking of the PrP binding pattern on the peptide-array.
The capability of the N-terminal peptide NTG to moder-
ately block binding of PrP to the peptide-array and also
moderately modulated PrPres formation in the supple-
mented -and pre-incubated PMCA assay (described
below) necessitates re-evaluation of the previously deter-
Effects of peptides on PrP to peptide-array binding pattern Figure 2
Effects of peptides on PrP to peptide-array binding pattern. No effect (A) on the peptide-array binding pattern and 
intensities was observed when PrP was pre-incubated with peptide CO (green line) compared to non-peptide pre-incubated 
PrP binding (grey bars). Only moderate inhibition of the binding pattern (B) was observed when PrP was pre-incubated with 
either peptide NTG (blue line) or peptide AM (orange line), whereas almost complete inhibition was observed when PrP was 
pre-incubated with either peptide OR (blue line), TD2 (green line) or CT (orange line). Minimal peptide concentration needed 
for blocking was determined (Table 1).
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mined consensus domain [33-GWNTG-37] [15]. Instead
of this common consensus domain two binding domains
seem present in the N-terminus. Binding motifs deter-
mined by motif-grafted antibodies [42] suggests that the
domain of interest is [27-RPKPGGG-33], which encom-
passes most of the proposed glycosaminoglycan binding
motif [25-KKRPK-29] [16].
These results confirm the importance of the previously
mapped domains [15] located within the first high bind-
ing area [PHGG] (octarepeat) and [102-WNK-104], as
well as the importance of the C-terminal low binding
domain [192-TTTTKGENFT-202] in PrP self-interaction.
To a lesser extent the involvement of the N-terminal gly-
cosaminoglycan binding motif contained within domain
[27-RPKPGGG-33] and amyloidogenic motif [116-
AGAAAAGA-123] in interaction is confirmed. Interest-
ingly peptide CO, encompassing the previously mapped
domain [140-PLIHFGNDYE-149] did not influence bind-
ing of PrP to the peptide-array.
PrP peptides modulation of PrPres formation in the PMCA-
assay
The peptides analyzed in the prion protein peptide-array
were also studied for their modulating capacity in the
sheep PrP protein misfolding cyclic amplification
(PMCA) assay [9,10,43] using sheep brain homogenates
from confirmed scrapie-positive and scrapie-negative
sheep in one round of sonication cycles. To test the influ-
ence of the peptides on conversion, peptides were either
added after combining the scrapie positive -and negative
brain homogenates (peptide supplemented PMCA) or
alternatively peptide was added first to the scrapie-nega-
tive brain homogenate before addition of the scrapie-pos-
itive material (peptide pre-incubated PMCA). This
allowed us to assess if the effect of the peptides on conver-
sion was dependant on the first rapid interaction between
PrPC and PrPSc [14] or not. Peptide was added in several
molar ratios, relative to the calculated total amount of
PrPC present in the reaction. PrPSc specific proteinase-K
(PK) resistant fragments were quantified by Western blot-
ting.
Peptide supplemented PMCA
Addition of peptide after mixing scrapie positive -and neg-
ative brain homogenates resulted in a dose dependant
increase of PK resistant PrP (PrPres) after sonication for
four [NTG, OR, TD2 and AM] of the six peptides tested
(results summerized in Table 2). In general the amount of
newly formed PrPres  roughly ranged between 2-fold
(standard reaction) up to 8-fold as compared to the input
amount of PrPSc. Addition of a large molar excess of pep-
tide NTG (Figure 3a) resulted in a significant increase in
PrPres formation in a dose dependant manner at molar
excesses of 5.000 (p = 0.0161) and 25.000 (p = 0.0007).
Addition of peptide OR (Figure 3b) resulted in the largest
increase of PrPres. However, in contrast to the other pep-
tides the effect was inversely dose dependant and signifi-
cant at molar excesses of 500 (p < 0.0001) and 1000 p =
0.0001). Molar excesses below 500 of peptide OR did not
result in significant increase of PrPres as with higher molar
excess of this peptide. Addition of peptide TD2 (Figure 3c)
resulted in a slight to moderate increase in PrPres forma-
tion. PrPres increase was significant only at a molar excess
of 25.000 (p = 0.0027). Addition of peptide AM (Figure
3d) resulted in a moderate and significant increase of
PrPres, but only when peptide was added at a molar excess
of 5.000 (p = 0.0012). Addition of either peptide CO (Fig-
ure 3e) or CT (Figure 3f) did not significantly influence
PrPres formation at the tested molar excesses. However it
does seem that these peptides slightly inhibit PrPres forma-
tion at molar excesses of 1000 and 5000 respectively.
Peptide pre-incubated PMCA
Pre-incubating scrapie-negative brain homogenate with
peptide before initiating conversion with scrapie-positive
brain homogenate, surprisingly resulted in increased for-
mation of proteinase-K resistant PrP (PrPres) after sonica-
tion for five [NTG, TD2, AM, CO and CT] of the six
peptides tested (results summerized in Table 2) generally
in a dose dependant manner. However, compared to the
peptide supplemented PMCA assay results differed for
several of the peptides. Pre-incubation with peptide NTG
(Figure 4a) resulted in a slight but significant increase of
PrPres at the optimal molar excess of 5.000 (p = 0.0076).
In contrast to peptide supplemented PMCA reactions, pre-
incubation with peptide OR (Figure 4b) did not signifi-
cantly affect PrPres formation at any of the molar excesses
tested. Pre-incubation with peptide TD2 (Figure 4c)
induced a moderate but significant increase of PrPres at
molar excesses 5.000 (p = 0.0048) and 25.000 (p =
0.0113), with an apparent optimum at 5.000. Whereas
peptide AM induced amplification of PrPres optimally at
molar excess 5.000 in the supplemented PMCA assay, pre-
incubation with this peptide (Figure 4d) resulted in a
slight but significant dose dependant increase in PrPres at
molar excesses 5.000 (p = 0.0362) and 25.000 (p =
0.0044). Pre-incubation peptide CO (Figure 4e) resulted
in a significant moderate or slight increase in PrPres at
molar excesses 1.000 (p < 0.0001) and 25.000 (p =
0.0496). However, increase of PrPres at molar excess of
1.000 was larger and unmistakably more significant than
at the higher molar excess, suggesting an inverse dose
dependant increase of peptide induced PrPres formation.
Finally, pre-incubation of SNH with peptide CT (Figure
4f), also resulted in a significant inverse dose dependant
increase of PrPres at the molar excess of 1.000 (p = 0.0006).
PMCA assay negative controls
Even though each PMCA assay setup revealed at least one
PrP specific peptide incapable of modulating PrPres forma-
tion, additional negative controls were performed. To ruleBMC Biochemistry 2009, 10:29 http://www.biomedcentral.com/1471-2091/10/29
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Effects of peptide supplementation on PrPres formation in ovine PMCA Figure 3
Effects of peptide supplementation on PrPres formation in ovine PMCA. Bar graphs depicting PrPres formation of a 
standard PMCA reaction compared to a PMCA reaction supplemented with different molar excess amounts of peptide NTG 
(A), peptide OR (B), peptide TD2 (C), peptide AM (D), peptide CO (E) and peptide CT (F). For each peptide its specific corre-
sponding standard is depicted (grey bar). In order to determine the optimal molar excess of octarepeat peptide OR in the sup-
plemented PMCA, a single test with peptide OR added at molar excess 1, 10, 100 and 250 was performed. The amounts of 
PrPres in these reactions were comparable to the standard. As an example results at molar excess 1 and 100 are depicted in 
graph B. The number of independent measurements (n), the median and s.e.m. for each peptide and molar excess are summa-
rized in Table 2. An unpaired Student's t-test was performed to determine whether PrPres formation with peptide was signifi-
cantly different to the corresponding standard PrPres formation. P-values are listed in Table 2 and significant differences are 
marked; p-values between 0.05 and 0.001 with *, p-values between 0.001 and 0.0001 with ** and p-values = 0.0001 with ***.
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out the possibility that factors other than PrP sequence
specificity could be responsible for the observed results,
the isoelectric point, net charge and average hydrophilic-
ity were determined for each peptide (data not shown).
Comparison revealed no clear correlation between these
non-sequential features and the observed effects in the
PMCA assay. Therefore the following additional negative
controls were performed; In order to determine whether
addition of just a random peptide is sufficient for modu-
lating PrPres formation an unrelated peptide (canine parvo
virus specific sequence peptide DGAVQPDGGQPA-
VRNER) was used in both testing setups described above.
Addition of this peptide did not affect PrPres formation in
either of the two PMCA assay setups (data not shown) at
various concentrations, indicating that the observed
increases in PrPres were a result of the specific PrP derived
peptide amino acid sequences added to the reactions. Fur-
thermore, PMCA assays were also performed for each pep-
tide without scrapie positive homogenate, to determine
whether  de novo PrPres could be formed when the PrP
derived peptide was combined with PrPC. Peptide was
added at the optimum (in the supplemented PMCA)
molar excess for peptide NTG (1.000), OR (500) and AM
(5.000). While peptides TD2, CO and CT were added at
the highest molar excess (25.000) used in the in the
PMCA assays described above. No significant conversion
induced by either of these peptides was detected after PK
digestion (data not shown), showing that only addition of
scrapie-positive brain homogenate resulted in initiation
of the conversion reaction.
Discussion
In a previous study [15] we showed that ovine PrP binds
to itself and mapped several domains using ovine (and
bovine) prion protein derived peptide-arrays, yielding a
PrP-specific binding pattern for soluble (monomeric) PrP
that could be blocked by several PrP-specific monoclonal
antibodies. The current study shows that the different PrP
derived synthetic peptides exert different effects on bind-
ing in a peptide-array assay and on conversion of PrPC to
PrPres in the PMCA assay. In order to better interpret the
PMCA data, one needs to consider the effects of sonica-
tion in the PMCA. It may be expected that after the first
incubation cycle, sonication simply results in shearing the
Table 2: Peptide modulation of supplemented -and pre-incubated PMCA assay
complemented PMCA-assay pre-incubated PMCA-assay
peptide m.e.1 median s.e.m. n2 sign.3 median s.e.m. n2 sign.3
NTG 1000 2.07 0.24 3 4.15 0.60 5
5000 3.56 0.73 3 * 5.91 0.76 5 **
25000 4.68 1.26 3 ** 4.13 0.63 5
OR 500 6.26 1.27 4 *** §n.t.
1000 4.61 0.87 5 *** 3.85 0.54 4
5000 2.74 0.68 4 4.44 0.85 4
25000 2.57 0.33 2 3.99 1.19 4
TD2 1000 3.71 0.73 8 n.q. 1.73 0.35 4
5000 3.00 0.93 8 3.15 0.33 4 **
25000 4.63 0.62 8 ** 2.91 0.34 4 *
AM 1000 1.92 0.27 3 4.36 0.28 7
5000 4.03 0.34 3 ** 5.38 0.76 7 *
25000 2.36 0.46 3 5.63 0.50 7 **
CO 1000 1.56 0.02 2 8.59 0.46 5 ***
5000 2.02 0.58 2 4.95 1.43 5
25000 1.97 0.22 2 6.09 1.53 5 *
CT 1000 1.80 0.21 2 6.21 0.39 5 **
5000 1.41 0.29 2 5.23 1.76 5
25000 2.85 1.12 2 4.77 0.92 5
1 amount of molar excess of peptide compared to PrPC tested in the PMCA assay
2 numbers of independent measurements performed
3 comparison of conversion ratios of the peptide supplemented -or pre-incubated PMCA and their corresponding standards using the unpaired 
Student's t-test (p-values < 0.05 are considered statistically different). Significantly different values are marked; p-values between 0.05 and 0.001 
with *, p-values between 0.001 and 0.0001 with ** and p-values ≤ 0.0001 with ***. The p-value of a comparison that was not quite significantly 
different is marked with n.q.
§n.t. = not testedBMC Biochemistry 2009, 10:29 http://www.biomedcentral.com/1471-2091/10/29
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Effects of peptide pre-incubation on PrPres formation in ovine PMCA Figure 4
Effects of peptide pre-incubation on PrPres formation in ovine PMCA. Bar graphs depicting PrPres formation of a 
standard PMCA reaction compared to a PMCA reaction in which the scrapie negative homogenate was pre-incubated with 
peptide with different molar excess amounts of peptide NTG (A), peptide OR (B), peptide TD2 (C), peptide AM (D), peptide 
CO (E) and peptide CT (F) before adding scrapie positive homogenate. For each peptide its specific corresponding standard is 
depicted (grey bar). The number of independent measurements (n), the median and s.e.m. for each peptide and molar excess 
are summarized in Table 2. An unpaired Student's t-test was performed to determine whether the PrPres formation with pep-
tide was significantly different to the corresponding standard PrPres formation. P-values are listed in Table 2 and significant dif-
ferences are marked; p-values between 0.05 and 0.001 with *, p-values between 0.001 and 0.0001 with ** and p-values ≤ 
0.0001 with ***.
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elongated PrPSc which releases the peptide (Figure 5). This
results in multiple seeds for the following incubation
cycle so that after the first sonication cycle, conditions for
both the pre-incubated and the supplemented PMCA can
be considered identical. This is however not in agreement
with the obtained results (discussed below). Therefore we
have devised a more intricate schematic (Figure 6) to bet-
ter account for the observed differences between the pre-
incubated (Figure 6A) and supplemented PMCA (Figure
6B) for some of the peptides.
The conversion process is a succession of distinct steps,
which most likely starts with the multimerisation of PrPC.
Wille et al. used electron crystallography to characterize
the structure of two infectious variants of the prion pro-
tein [44]. By comparing projection maps of these two var-
iants a model featuring β-helices was devised. This model
was further refined by studying 119 all-β-folds observed
in globular proteins [3]. It was proposed that PrPSc should
adopt a β-sandwich, parallel β-helical architecture, or a
parallel left-handed β-helical fold. This left-handed β-hel-
ical folded PrP can readily form trimers, providing a natu-
ral template for a trimeric model of PrPSc and another
(similar)  β-helical model was proposed, which largely
explained species and strain-specificity [4]. In both mod-
els oligomerisation/trimerisation of PrPC precedes initia-
tion of conversion as depicted in Figure 7A, implying an
important role for PrPC self-interaction in the conversion
processes. Our data fits this multimerisation of PrPC.
Additionally, study of the amyloid-forming pathway
revealed a pre-amyloid state containing partially unfolded
monomers and dimers (PrPi) [45-50]. Whether PrPi is just
the partially unfolded state (monomers and dimers) of
PrPC or whether it is a pre-formed trimer before further
structural rearrangement towards PrPSc occurs (Figure 7B)
remains to be elucidated. Conversion is initiated by
recruitment of PrP to PrPSc (Figure 7C), after which PrP is
(further) rearranged to adopt the tertiary structure of the
PrPSc seed (Figure 7D). The elongated PrPSc is in turn capa-
ble to recruit and convert further PrP (Figure 7E). Taking
these studies into account and their implications for con-
version allows for a more detailed interpretation of the
data presented in this study., Herein the peptide-array
data is indicative for the effects on soluble PrP (PrPC-PrPC
interaction), whereas the PMCA assay may be indicative
for effects on PrP interactions (self- and PrPC-PrPSc interac-
tion) as well as interactions with chaperoning or inhibit-
ing molecules. All six PrP-derived peptides tested affected
conversion in either the supplemented and/or pre-incu-
bated PMCA assay, whereas binding to the peptide-array
was only completely abolished by three peptides [OR,
TD2 and CT]. Taken together, this study shows that the
previously determined self-interaction domains of PrPC
are of importance at several different phases in the conver-
sion reaction.
Ovine peptide-array analysis previously revealed two high
binding areas within PrP [15] of which the first high bind-
ing area encompasses the octarepeats, more specifically
the consensus domain P(H)GG. This study showed that
the octarepeat peptide (OR) was capable of blocking the
binding pattern of PrP to the peptide-array, probably as a
result of peptide-induced changes in the tertiary structure
of the N-terminal tail and thus affecting PrPC self-interac-
tion. Only in the supplemented PMCA assay, a dose
dependant and significant increase in PrPres is observed.
The octarepeats can modulate [51-55] but are not a neces-
sity for the molecular processes underlying conversion
[21,56]. Interaction between PrPC and PrPSc seems almost
instantaneous [14], which would leave the peptide free to
interact with the PrPC - PrPSc complex as a whole or with
co-factors present in the homogenates. Because the octare-
peat stabilizes the interaction of PrPC with the LRP-LR
receptor [57], it seems that peptide OR indirectly affects
the conversion process, either by affecting PrPi stability/
formation (Figure 7B) or by stabilizing PrPi interaction
with PrPSc (Figure 7C). Furthermore, a di-peptide contain-
ing the octarepeat self-aggregates into nanometric fibrils
[58] and these may also be formed in the supplemented
PMCA assay. Combined with our data, we propose that
the flexible N-terminal tail containing the octarepeat
region stabilizes PrPC-PrPSc interaction during conversion
and that free peptide OR forms nanometric fibrils mim-
icking and increasing PrPC-PrPSc stabilization, thus aiding
subsequent conversion. Also part of the peptide-array first
high binding area is binding domain 2 ([102-WNK-104],
Figure 1) and the data presented here shows that pre-incu-
bation of the peptide TD2 (containing [102-WNK-104])
with PrP abolished binding of PrP to the peptide-array.
This indicates the importance of this domain in PrPC self-
interaction (Figure 7A and possibly 7B). Increased PrPres-
production was observed in both the supplemented -and
the pre-incubated PMCA-assay. The mechanism by which
the peptide stimulates PrPres formation may simply be due
to peptide enhanced interaction between separate PrP
molecules. Alternatively, peptide TD2 could aid unfolding
and/or refolding of PrPC  during conversion; binding
domain 2 [102-WNK-104], together with the amyloidog-
enic motif, is part of the region of PrPC that is partially
unfolded and refolded during oligomerization of PrPC
into a β-sheet-rich soluble isoform of PrP [47].
The second high binding area in the peptide-array con-
tains the domain [140-PLIHFGNDY-148] (domain 3, Fig-
ure 1). This study shows that the peptide CO containing
the domain [140-PLIHFGNDY-148] does not affect bind-
ing of PrP to the peptide-array at all, thereby ruling out
direct involvement in PrPC self-interaction. Several studies
have established that polymorphisms at sheep PrP amino
acid position 136, 154 and 171 surrounding [140-PLIHF-
GNDY-148] are most relevant in differential TSE suscepti-BMC Biochemistry 2009, 10:29 http://www.biomedcentral.com/1471-2091/10/29
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Schematic representation of one incubation/sonication cycle of PMCA Figure 5
Schematic representation of one incubation/sonication cycle of PMCA. Peptide is allowed to form a bond with PrPC 
(1), resulting in all PrPC binding peptide(s) (pre-incubation with an excess of peptide). The conversion reaction is initiated by 
adding PrPSc to the 'sensitized' PrPC (2). It is possible that the peptide remains associated with the formed PrPres during conver-
sion (3). Sonication (4) shears PrPres, but does not necessarily release peptide from 'sensitized' PrPC and probably also not from 
the elongated PrPSc (#). The PrPres fragments are in turn capable of recruiting and converting 'sensitized' PrPC (5) during the 
next incubation cycle.
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Adapted schematic representation of one incubation/sonication cycle of PMCA Figure 6
Adapted schematic representation of one incubation/sonication cycle of PMCA. Pre-incubated PMCA (A): pep-
tide is allowed to form a bond with PrPC (1), resulting in all PrPC binding peptide (pre-incubation with an excess of peptide). 
The conversion reaction is initiated by adding PrPSc to the 'sensitized' PrPC (2). It is likely that the peptide is incorporated in 
formed PrPres during conversion (3). Sonication (4) shears PrPres, but does not release peptide from 'sensitized' PrPC and prob-
ably not from the elongated PrPSc (#). The PrPres fragments (some with peptide incorporated) are in turn capable of recruiting 
and converting 'sensitized' PrPC (5) during the next incubation cycle. Supplemented PMCA (B): the conversion reaction is 
first initiated by combining PrPC and PrPSc (1). Peptide is immediately added (2), which can bind to either PrPC or PrPSc sepa-
rately, but is probably only effective when binding both. PrPC is converted, possibly releasing the peptide in the process (3). 
Sonication (4) shears PrPres, probably releasing the peptide if it is still bound after step 3. The PrPres fragments (unlikely with 
peptide incorporated, #) are in turn capable of recruiting and converting PrPC (5) during the next incubation cycle. Even though 
PrPC, PrPres and peptide are all present after sonication, it is likely that fist the PrPC-PrPSc complex is formed (1) before interac-
tion with peptide (2) occurs. However, if the peptide is capable of 'sensitizing' PrPC, the reaction proceeds as described for the 
pre-incubated PMCA reaction (6). After addition of all ingredients in the first cycle the pre-incubated -and supplemented 
PMCA reactions will have both unbound and bound peptide available for the following sonication-incubation cycles.
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bility [5,59-63] and that stability of this PrP region is a
crucial determinant in whether PrPC is converted [40,64]
(affecting species-barrier and/or scrapie susceptibility).
Therefore peptide CO induced PrPres formation in the pre-
incubated PMCA assay is either due to this core region
peptide facilitating binding of PrPC to PrPSc or the peptide
affects the stability of this region of PrPC (interacting with
the 'self-domain' or another domain of PrP) thereby facil-
itating refolding of PrP.
The N-terminal peptide NTG (containing the gly-
cosaminoglycan binding motif) only moderately affects
binding of PrPC throughout the peptide-array, suggesting
that interaction of the peptide with PrPC results either in
slight changes in the tertiary structuring affecting solubil-
ity of PrPC or in diminished availability of the previously
determined domains [15] for interaction with the pep-
tide-array. Intriguingly, peptide NTG induces PrPres forma-
tion in both the supplemented (dose dependant) and pre-
incubated (dose optimum) PMCA assay. The gly-
cosaminoglycan heparan sulphate proteoglycan (HSPG)
and pentosan polysulphate (PPS) stimulate PrPres forma-
tion in vitro and suggests that free glycosaminoglycans
acted as a contact-mediator allowing interaction of PrPC
and PrPSc [65]. The N-terminal peptide NTG likely indi-
rectly affects in vitro conversion either by mimicking gly-
cosaminoglycan binding to domain [27-RPKPGGG-33]
or by recruiting glycosaminoglycans onto PrPC, facilitat-
ing conversion of PrPC into new PrPSc after seeding. These
studies and our PMCA assay data strongly implicate gly-
cosaminoglycans as an important cofactor in the conver-
sion process.
The ability of peptide AM, which encompasses the amy-
loidogenic motif [116-AGAAAAGA-123], to moderately
block binding of PrP to the peptide-array was somewhat
surprising, since we previously showed that the amy-
loidogenic motif was not involved in PrP self-interaction
[15]. Peptide AM mainly inhibits binding of PrP to the
peptides covering the N-terminal part of the mature PrP
protein, suggesting that peptide AM interacts with one (or
more) of the other previously determined binding
domains. In contrast to earlier reports [41,66,67], we
observed that peptide AM (containing the amyloidogenic
motif) slightly but significantly increased PrPres formation
in both the pre-incubated -and supplemented PMCA.
However, all these inhibiting peptides contained two or
more additional amino acids of the putative aggregation
sites (flanking the amyloidogenic motif) implicated in
aggregation/oligomerisation [68], suggesting inhibition
by these peptides is due to interference with aggregation/
oligomerization. Additionally, differences between the
used conversion systems (i.e. availability of cofactors) are
likely to play a role as well. The peptide AM used in this
study specifically focuses only on the amyloidogenic
motif. Our data suggests that peptide AM interacts with
the N-terminal tail of PrPC (octarepeat motif or [102-
WNK-104]), probably altering its tertiary structure and
facilitating the proposed stabilizing effect of the N-termi-
nal tail. Alternatively, peptides containing only the amy-
loidogenic motif are also capable of forming a β-sheet rich
layer at the water-air interface when sonicated [69] and
peptide AM may form a β-sheeted backbone that interacts
with the PrPC-PrPSc complex, mimicking and/or comple-
menting the proposed stabilizing effect of the N-terminal
tail.
Peptide CT overlaps most of the third alpha helix of PrPC
as well as the second glycosylation site and the second
cysteine involved in the di-sulphide bridge formed in
PrPC. The capacity to completely block PrP binding to the
peptide-array suggests that the domain [225-SQAY-228] is
of importance in PrPC self-interaction. This study shows a
slight significant increase in PrPres formation when pep-
tide CT is pre-incubated with scrapie negative brain
homogenate. This contradicts results using a similar pep-
tide capable of inhibiting cell free conversion [41]. How-
ever, this inhibiting peptide is four amino acids larger
than peptide CT, which may account for the difference in
effects and/or it may just be due to the differences in
experimental technique between the cell free conversion
and the PMCA assay. This seems to be corroborated by the
observation that in the supplemented PMCA (setup clos-
est resembling conditions in cell free conversion [41])
peptide CT seems to slightly inhibit PrPres formation albeit
not significantly. Fibrillization of a human PrP peptide
fragment is hindered by disulfide bridge formation
between two peptides [70] or when an additional
disulfide bridge is introduced [34], which indicates that
peptide CT (when pre-incubated with PrPC) likely com-
promises the disulfide bridge, destabilizing PrPC, which
consequently promotes trimerisation or formation of a
conversion intermediate (Figure 7B) and thus facilitating
conversion.
In the PMCA-assay all peptides revealed an inducing effect
on PrPres formation in the supplemented -and/or pre-
incubated PMCA-assay. Above possible explanations for
these effects have been discussed for each peptide. How-
ever it can not be ruled out that the peptides may have had
an opposite effect; instead of interacting with PrP, peptide
may have interacted with possible conversion inhibitory
factors present in the homogenate, thus indirectly allow-
ing conversion to take place more efficiently. Identifying
these possible 'natural' inhibitory factors may prove an
alternative line of investigation towards the underlying
mechanisms involved in prion replication and may pro-
vide additional targets for future prion therapy.BMC Biochemistry 2009, 10:29 http://www.biomedcentral.com/1471-2091/10/29
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Conclusion
The binding domains found for ovine PrPC using a prion
protein peptide-array are primarily indicative of prion
protein self-interaction. Apparently several specific self-
interactions between individual PrP molecules occur,
which include both PrPC-PrPC as well as PrPC-PrPSc inter-
actions. The data presented here imply an influence of
binding domain [140-PLIHFGNDY-148] on the stability
of the region of PrP previously determined to be involved
in the species-barrier and/or susceptibility to scrapie. Fur-
thermore our data indicates a stabilizing function for the
octarepeats region (N-terminal tail) in PrPC-PrPSc interac-
tion and thus improving subsequent conversion. Our data
further suggests that the N-terminal glycosaminoglycan
binding motif [27-RPKPGGG-33] affects the conversion
process indirectly, and implicates glycosaminoglycans as
an important cofactor in prion disease pathogenicity. Pep-
tide AM containing the amyloidogenic motif indirectly
affects conversion either by aiding and/or complementing
the proposed stabilizing function of the N-terminal tail of
PrPC. Finally, the data implicates direct involvement of
the two binding domains [102-WNK-104] and [225-
SQAY-228] in self-interaction between PrPC molecules
preceding binding to PrPSc and subsequent conversion.
Therefore these two domains may prove prime targets for
development of new therapeutic strategies. Our results
emphasize the importance of the stability of the PrPC-PrPC
and PrPC-PrPSc interactions in PrP conversion, which is an
essential determinant in the effects of disease associated
mutations, as well as the species-barrier. Focussing on the
(stabilizing) self-interaction domains of PrP and the sub-
sequent conversion processes may lead to further thera-
Schematic representation of likely steps in prion protein conversion Figure 7
Schematic representation of likely steps in prion protein conversion. Preceding conversion a multimer of PrPC mole-
cules is formed [A]. Possibly a dimer is formed and both monomeric -and dimeric PrP is partially refolded before forming the 
structural subunit of a fibril; trimeric PrP. PrPC may however first form a trimer before partially unfolding and/or refolding. Par-
tial unfolding/refolding is at the basis of forming an intermediate isoform of PrP (PrPi) [B]. PrPi can subsequently interact with 
the conversion seed (PrPSc) [C], which allows conversion of PrP into PrPSc. Several PrPi may have to be 'stacked' onto the con-
version seed before conversion of the first PrPi bound can occur. During conversion PrPi is further refolded into PrPSc, its ter-
tiary structure adapted to that of the conversion seed (D). The newly elongated PrPSc in turn can act as a seed for further 
conversion of PrP (E). The bars beneath the schematic denote for which conversion processes the peptide-array results (white 
bar) and PMCA assay results (shaded bar) are indicative.
PrPC PrPi PrPSc
PMCA assay peptide-array
A
CD
E
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peutic strategies with the possibility to leave the
physiological function of the prion protein unaffected.
Methods
MBP-PrP construction, expression and purification
The mature part of sheep PrP (ARQ) open reading frame
(ORF) was cloned into the pMAL Protein Fusion and Puri-
fication System (New England Biolabs) as described
before [15], resulting in the maltose binding protein
(MBP) fusion to the N-terminus of PrP (MBP-PrP). MBP-
PrP was expressed and purified by affinity chromatogra-
phy as described in the manual of the pMAL Protein
Fusion and Purifications System (method I; New England
Biolabs) To improve binding of MBP-PrP and to prevent
formation of interchain disulfide upon lysis (as suggested
in the protocol), β-mercaptoethanol was added. Quantity
and quality of the eluted MBP-PrP was determined before
use in the peptide-array by SDS-PAGE (12% NuPAGE,
Invitrogen). After separation the gel was either stained
with Sypro Orange (total protein stain, Molecular Probes)
or analyzed by Western blotting and immunodetection of
MBP-PrP with polyclonal antiserum R521-7 specific for
PrP [71].
Peptides
Peptides were synthesized with an acetylated N-terminus
and an amidated C-terminus as described before [71]. The
synthesized peptides were purified by high performance
liquid chromatography using mass spectrometric analysis
for identification. The resulting purified peptides were at
least 90% pure. All peptides dissolved well in water and
solutions were stored frozen. Sequential properties like
iso-electric point were calculated with the Peptide Prop-
erty Calculator made available online in the tools section
of Innovagen http://www.innovagen.se.
Peptide-array analysis
Synthesis of complete sets of overlapping 15-mer peptides
were carried out on grafted plastic surfaces, covering the
ovine PrP amino acid sequence of mature PrP (residues
25-234 [72]). Coupling of the peptides to the plastic sur-
face consisting of a 455-well credit-card size plastic (min-
icard) and subsequent ELISA analyses including
subsequent background correction, relative density value
calculation and binding pattern interpretation were per-
formed as described before [15,73]. This study also
showed that linking of MBP to PrP did not have any dis-
advantageous effects and therefore its properties are indic-
ative for PrP. Peptide blocking studies were performed by
pre-incubating the MBP-PrP with molar excesses of prion
peptides before incubating the PrP-peptide mixture as the
antigen on the minicard. Binding to the peptide-array was
considered relevant when at least at 3 consecutive pep-
tides optical density values of at least 2.5 times the back-
ground were observed.
Protein Misfolding Cyclic Amplification assay
The protein misfolding cyclic amplification (PMCA) assay
first described by Saborio et al. [9] and has been shown
applicable to amplify PrPSc from different sources [10,43].
In short; a 10% brain homogenate from a (confirmed)
scrapie-positive sheep (SPH) was diluted with 50-100
times in 10% (confirmed) scrapie-negative sheep brain
homogenate (SNH) after which the reaction was sub-
jected to one round of sonication-incubation cycles (24
hours; 48 cycles). To test the influence of the peptides on
conversion, the peptides were either added after combin-
ing the scrapie positive -and negative brain homogenates
(supplemented PMCA) or peptide was pre-incubated with
the scrapie-negative homogenate (pre-incubated PMCA)
before addition of the scrapie-positive brain homogenate.
The total amount of PrPC in the PMCA reaction was calcu-
lated based on the quantification of the amount of PrPC in
brain tissue [74]. The amount of peptide needed for a
reaction was calculated based on the total amount of PrPC
in the reaction, adjusted for the size difference between
peptide and PrPC, so that the amount of peptide added
represents various molar excesses of peptide molecules
relative to the total number of PrPC molecules present in
the reaction. The amount of formed PrPres was determined
after proteinase K digestion (100 μg/ml) of the PMCA
reaction and analysis by SDS-PAGE and subsequent West-
ern blotting. Standard detection of PrPres was performed
with monoclonal antibody 9A2 [75], except for PMCA
reactions containing peptide SAU14, which contains the
binding epitope of 9A2. In this case we used a proven
combination of monoclonal antibodies L42 [76] and
Sha31 [77]. To determine whether the determined
amounts of PrPres were significantly different in compari-
son to its corresponding standard PMCA-assay reaction,
an unpaired Student's t-test was performed and the p-
value calculated.
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